ACT NOW -
Use VETMEDIN at first clinical signs to keep dogs going
Proven efficacy in clinical trials
VETMEDIN is approved for use as first-line therapy to manage mild, moderate, or severe signs of congestive heart failure (CHF).1 The effectiveness of VETMEDIN in managing dogs with CHF has been thoroughly investigated in FDA-licensing and other clinical studies.1-3 Efficacy trials support the benefits of VETMEDIN when used at the first clinical signs of CHF.2-4
Trial results document the ability of VETMEDIN to improve and lengthen life in dogs with CHF. The QUEST* trial indicated that VETMEDIN virtually doubled survival times.3
In addition, trials showed that VETMEDIN quickly reduced clinical signs—within 1 week.2 Improving quality of life for their dogs is an important factor to pet owners in managing CHF.
Overall, extensive study data indicate that use of VETMEDIN as primary treatment allows dogs with CHF to lead happier, healthier, and longer lives.1-4
Important safety information
VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.
The safety of VETMEDIN has not been established in dogs with:
- Asymptomatic heart disease
- Heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy
- Dogs younger than 6 months of age
- Dogs with congenital heart defects
- Dogs with diabetes mellitus or other serious metabolic diseases
- Dogs used for breeding or pregnant or lactating bitches
The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. If side effects should occur, pet owners should contact their veterinarian.
*Clinical studies were completed using VETMEDIN capsules. In the US, only the chewable tablets are licensed. Both the capsules and chewable tablets contain the same pharmaceutical ingredient, pimobendan, and are considered equivalent for clinical use. Bioequivalence, however, has not been shown.
References:
1. VETMEDIN® (pimobendan) Chewable Tablets [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2007. 2. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261. 3. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22(5):1124–1135. 4. Gordon SG, Miller MW, Saunders AB. Pimobendan in heart failure—a silver bullet? J Am Anim Hosp Assoc. 2006;42(2):90–93.
VETMEDIN is a registered trademark of Boehringer Ingelheim Vetmedica GmbH,
licensed to Boehringer Ingelheim Vetmedica, Inc.